Fierce Pharma

APRIL 11, 2024

As lawmakers, biopharma companies and others try to stabilize vulnerable pharma supply chains, drug shortages have become about as bad as they’ve ever been in the U.S. | as of 2024’s first quarter—the highest number recorded since ASHP began tracking shortage data back in 2001. . |

Biopharma 307

Biopharma Pharma 307

European Pharmaceutical Review

DECEMBER 20, 2023

1 The changes form part of the 2020 Pharmaceutical Strategy for Europe will impact pharma and biopharma companies operating in Europe. However, it is clear that changes are likely to have meaningful impacts for biopharma players if adopted. analysis (Source: L.E.K) About the authors Sean Dyson is a Partner in L.E.K.’s

Biopharma 82

Biopharma Pharmaceutical Medicine Manufacturing 82

Clarivate

OCTOBER 31, 2023

What do the years 2001, 2007, 2014, and 2022 have in common? These years witnessed significant troughs in pharma financing, a drop in the capital markets, and an IPO window that remained firmly shut. In short, the biotech bubble had burst. Pfizer’s $11.6 Pfizer’s $11.6

Pharma 52

Pharma Biopharma Marketing Healthcare 52

European Pharmaceutical Review

DECEMBER 12, 2023

Yannis Morel, Executive Vice President of product portfolio strategy and business development of Innate Pharma SA, offers insight on engineering antibodies to develop antibody-based NK cell therapeutics. As a biotech, what work does Innate Pharma do in the biopharma industry?

Pharma 105

Pharma Engineering Safety Patients 105

European Pharmaceutical Review

DECEMBER 19, 2022

Chris’s practice for biopharma and pharma clients includes advising on the complex regulatory frameworks and the availability of valuable IP regulatory rights such as orphan‑drug market exclusivity, paediatric rewards, SPCs and regulatory data protection rights. Directive 2001/83 (as amended). EMA Biosimilars Q&A.

Medicine 52

Medicine Biopharma Safety Food 52

PM360

AUGUST 24, 2023

Later in his career he transitioned to the agency side and launched Weisscom Partners in 2001, which ultimately evolved to Real Chemistry. Bigfoot Biomedical Ethicon, a Johnson & Johnson MedTech Company Medtronic Zimmer Biomet COMPANY OF THE YEAR: SPECIALTY PHARMA/BIOTECH argenx Chiesi GRD Cullinan Oncology, Inc.

Marketing 52

Marketing Education Media Healthcare 52

PM360

OCTOBER 5, 2023

Later in his career he transitioned to the agency side and launched Weisscom Partners in 2001, which ultimately evolved into Real Chemistry. PRODUCT LAUNCH OF THE YEAR NEXTSTELLIS (Mayne Pharma and EVERSANA INTOUCH) RELAUNCH/REVITALIZATION OF THE YEAR VRAYLAR (AbbVie Inc. Braun Medical, Inc.

Education 52

Education Marketing Media Biopharma 52